SelectMDx is Cost-Effective Test for Prostate Cancer Biopsy Selection, Dutch Researchers Find

SelectMDx is Cost-Effective Test for Prostate Cancer Biopsy Selection, Dutch Researchers Find
The SelectMDx test for prostate cancer reduces overdiagnosis and overtreatment in men at risk of prostate cancer compared to PSA testing alone, MDxHealth announced. By cutting the number of unnecessary biopsies, the test brings down total costs per patient while improving quality of life, according to the Dutch study, “Cost-effectiveness of a new urinary biomarker-based risk score

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *